Metoprolol Succinate Tablet, Extended Release
Product Images NDC 71610-558

6 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 71610-558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 25 mg (71610 0555 45)

Bottle Label 25 mg (71610 0555 45)
Metoprolol Succinate ER USP 25 mg extended-release oral tablets packaging label. The label includes storage instructions, manufacturer Novast Laboratories Ltd. in Hong Kong, and packager Aphena Pharma Solutions in Cookeville, TN. It specifies that the product is prescription only and comes in a 45-tablet package.*
FDA Label Image

Bottle Label 100 mg (71610 0558 45)

Bottle Label 100 mg (71610 0558 45)
Metoprolol Succinate ER USP 100 mg extended-release tablets, package of 45 tablets. Label shows storage instructions, manufacturer as Novast Laboratories Ltd., and labeler as Aphena Pharma Solutions - Tennessee, LLC located in Cookeville, TN. Includes barcode and batch information.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Image-01 (Image 01)

Image-01 (Image 01)
Chemical structure diagram showing the molecular composition of Metoprolol Succinate, including the metoprolol moiety and succinate portion, as represented by detailed chemical groups and bonds.*
FDA Label Image

Image-02 (Image 02)

Image-02 (Image 02)
A forest plot chart titled 'Results for Subgroups in MERIT-HF' showing three outcomes: Total Mortality, Total Mortality or All-Cause Hospitalization, and Total Mortality or Hospitalization for Heart Failure. The chart compares Metoprolol Succinate Extended-Release Tablets versus placebo across various subgroups, indicating relative risk and 95% confidence intervals for each subgroup's outcome.*
FDA Label Image

Image-03 (Image 03)

Image-03 (Image 03)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.